Novavax, Inc. announced that its partners secured regulatory clearance for the XFG-adapted Nuvaxovid vaccine in the United States, European Union and Japan. Shares dipped 0.6% to $9.00 as of 11:58 a.m. EDT.
Regulatory clearance is complete; royalties now depend on partner-led demand.
| Revenue channel | Economics | What changed |
|---|---|---|
| Sanofi royalties | High teens–low 20s % of global net sales | U.S. and EU seasonal approvals enable sales |
| Takeda | Royalties plus annual approval milestones | Japan approval supports 2026–2027 season |
| Sanofi supply | Recorded as product sales | Commercial supply planned this season |
| Technology transfer | $75M potential milestone | Expected mid-2027 |
Excludes Sanofi supply sales, royalties and milestones.
Versus $751M at Dec. 31, 2025
| Q2 2026 | Value | Year-over-year |
|---|---|---|
| Total revenue | $57M | −76% |
| Product sales | $19M | +76% |
| Net loss | $53M | vs. $107M profit |
| Net R&D expense | $48M | −34% |
| SG&A expense | $27M | −39% |
+47% from $9.00
| High | $19.00 |
| Low | $7.00 |
| Ratings | 2 Buy · 1 Hold · 1 Sell |
Approvals remove regulatory risk, but the stock's muted reaction signals demand uncertainty. The core sensitivities are vaccine uptake, coverage policy, Sanofi execution and timing of royalty recognition. Management gives no Sanofi sales forecast.
Sources: Novavax Aug. 28 approval update and Aug. 6 financial results; Reuters Aug. 27 FDA report; Google Finance. Prices are delayed U.S. quotes at 11:58 EDT on Aug. 28, 2026.
The ADSs opened at $102.34, traded as low as $98.80, then recovered part of the decline.
The monitoring board found a numerical overall-survival imbalance between arms and judged further continuation unlikely to change efficacy.
Stage II high-riskStage IIIctDNA-positivePost-surgery| Measure | Latest | Investor signal |
|---|---|---|
| Q2 revenue | €105.6m | Down 59.5% year over year |
| Q2 R&D expense | €551.0m | Heavy oncology investment continues |
| Q2 net loss | €820.8m | Up 112% year over year |
| 2026 revenue guide | €1.6–€1.9bn | Already reduced in August |
| 2026 adjusted R&D guide | €2.0–€2.3bn | Capital allocation becomes more important |
| Share repurchase authorization | Up to $1.0bn | Potential downside buffer, market-dependent |
Liquidity can absorb program failure, but repeated negative readouts would compress pipeline valuation.
| Consensus | Buy |
| Average target | $121.51 |
| Median target | $129.75 |
| Low / high | $76.14 / $145.26 |
| Coverage | 20 analysts |
Snapshot checked Aug. 28; ratings predate the trial termination.
Bull case: the stop saves future study spending and cash is redirected to stronger assets. Bear case: the survival signal weakens confidence in personalized mRNA oncology and raises scrutiny across partnered programs.
Moderna and Merck validated the category. BioNTech kept most of the sympathy gain, compressing the gap to the existing analyst consensus.
| Program | Stage | Evidence | Investment read |
|---|---|---|---|
| Moderna/Merck intismeran | Phase 3 | Positive topline in 1,137 resected melanoma patients | Direct category validation |
| BioNTech BNT111 | Phase 2 | Positive response-rate endpoint vs historical control | Promising, not registrational proof |
| BioNTech autogene cevumeran | Phase 2 | Missed primary PFS endpoint in advanced melanoma | Platform outcomes can diverge |
Sources: Yahoo Finance, Reuters, BioNTech Q2 2026, S&P Global analyst poll via StockAnalysis. Market-value estimate uses the latest reported 251.2m shares. Analyst targets and consensus are estimates, not guarantees.
